Filing Manager
ACORN BIOVENTURES, L.P.
Reporting Manager
Anders Hove
Symbol
JSPR
Shares outstanding
28,047,019 shares
Disclosed Ownership
1,486,492 shares
Ownership
5.3%
Form type
SCHEDULE 13G/A
Filing time
26 Jan 2026, 15:29:02 UTC
Date of event
23 Jan 2026
Previous filing
02 Dec 2025

Quoteable Key Fact

"ACORN BIOVENTURES, L.P. disclosed 5.3% ownership in Jasper Therapeutics, Inc. Common Stock, $0.001 Par Value (JSPR) on 23 Jan 2026."

Quick Takeaways

  • ACORN BIOVENTURES, L.P. filed SCHEDULE 13G/A for Jasper Therapeutics, Inc. Common Stock, $0.001 Par Value (JSPR).
  • Disclosed ownership: 5.3%.
  • Date of event: 23 Jan 2026.

What Changed

  • Previous schedule filing date: 02 Dec 2025.
  • Current filing was accepted on 26 Jan 2026, 15:29.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
ACORN BIOVENTURES, L.P. 2.2% 624,326 0 624,326 Anders Hove Manager of General Partner
ACORN CAPITAL ADVISORS GP, LLC 2.2% 624,326 0 624,326 Anders Hove Manager
ACORN BIOVENTURES 2, L.P. 3.1% 862,166 0 862,166 Anders Hove Manager of General Partner
Acorn Capital Advisors GP 2, LLC 3.1% 862,166 0 862,166 Anders Hove Manager
Anders Hove 5.3% 1,486,492 0 1,486,492 Anders Hove Individually
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .